ArticleJAMA oncology2026

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.

Junjie Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.